Sun Pharma Acquires US Drugmaker Organon for $11.75 Billion

Q: What is the total value of the acquisition?

The acquisition is valued at approximately **$11.75 billion**.

Q: What will be the share price for Organon in this deal?

Organon's outstanding shares will be purchased at **$14.00** per share.

Original: Sun Pharma to acquire US drugmaker Organon in $11.75 billion all-cash deal

Business Standard•Apr 27, 20261 min

In a Nutshell

Sun Pharmaceutical Industries, based in India, has announced its acquisition of US-based Organon & Co for approximately $11.75 billion in an all-cash deal. The agreement includes purchasing Organon's outstanding shares at $14.00 per share, enhancing Sun Pharma's portfolio in women's health and biosimilars.

Key Points

01Sun Pharma is acquiring Organon for $11.75 billion.
02The deal values Organon at $14.00 per share.
03Organon specializes in women's health and biosimilars.
04This acquisition will provide Sun Pharma full ownership of Organon.
05Organon was spun off from Merck in 2021.

In-Article Ad

Full Summary

India's Sun Pharmaceutical Industries has entered into a definitive agreement to acquire Organon & Co, a US-based pharmaceutical company, for approximately $11.75 billion. This all-cash deal will see Sun Pharma purchasing all outstanding shares of Organon at $14.00 per share. The...

Key Figures

$11.75 billion

Total acquisition value

$14.00

Price per share for Organon

In-Article Ad

Why It Matters

This acquisition could lead to increased product offerings in women's health and biosimilars, potentially benefiting consumers with more treatment options.

Who is affected

Consumers seeking women's health products and biosimilars.

What to know

Consumers should stay informed about new products and services that may emerge from this acquisition.

FAQ

The acquisition is valued at approximately $11.75 billion.

Organon's outstanding shares will be purchased at $14.00 per share.

✦